Physiologic hemostatic substrates via native platelet receptors

Physiologic hemostatic substrates via native platelet receptors refers to the fundamental mechanism of primary hemostasis, where platelets adhere to and are activated by the damaged vessel wall [1]. This process is mediated by the interaction of platelet-specific receptors—most notably the Glycoprotein Ib-IX-V complex and Glycoprotein VI (GPVI)—with subendothelial ligands such as von Willebrand factor (vWF) and various types of collagen [2]. These initial binding events trigger intracellular signaling pathways that lead to platelet shape change, the release of pro-thrombotic granules, and the conformational activation of the integrin alpha-IIb beta-3 (GPIIb/IIIa) receptor [1,3]. The activation of GPIIb/IIIa allows for fibrinogen-mediated platelet-to-platelet aggregation, culminating in the formation of a stable hemostatic plug [3]. This pathway is a major focus of pharmacological intervention; antiplatelet drugs like P2Y12 inhibitors and GPIIb/IIIa antagonists are used to prevent pathological thrombosis in cardiovascular diseases [4]. Conversely, emerging synthetic platelet technologies aim to mimic these interactions to treat acute hemorrhage by targeting exposed substrates at injury sites [5]. [1] Li Z, et al. Arterioscler Thromb Vasc Biol. 2010; [2] Farndale RW, et al. J Thromb Haemost. 2004; [3] Ruggeri ZM. Nat Med. 2002; [4] Patrono C, et al. Chest. 2008; [5] Modery-Pawlowski CL, et al. Biomaterials. 2013.

Other names

Platelet adhesion and activation pathwayPrimary hemostasis pathwayPlatelet-subendothelial interactionPlatelet-collagen-vWF axisHemostatic plug formation

Inhibition of platelet adhesion, activation, or aggregation by targeting specific receptors (e.g., P2Y12, GPIIb/IIIa, PAR1) or ligands (e.g., vWF) involved in the hemostatic response.